Search Results

Susceptibility of gram-negative isolates collected in Taiwan to imipenem/relebactam and comparator agents – SMART 2018–2021.

• Authors : Wise, Mark G.; Karlowsky, James A.; Chen, Wei-Ting

Subjects: IMIPENEM; GRAM-negative bacteria; CARBAPENEMSTAIWAN

• Source: Journal of the Formosan Medical Association; Mar2024, Vol. 123 Issue 3, p400-407, 8p

Record details

Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020–2022).

• Authors : Sader, Helio S.¹ (AUTHOR) ; Carvalhaes, Cecilia G.¹ (AUTHOR); Kimbrough, John H.¹ (AUTHOR)

Subjects: *BETA-lactamase inhibitors; *IMIPENEM; *WHOLE genome sequencingEASTERN Europe; WESTERN Europe

• Source: International Journal of Antimicrobial Agents. Apr2024, Vol. 63 Issue 4, pN.PAG-N.PAG. 1p.

Record details

Epidemiology and antibiotic resistance of prosthetic joint infections according to time of occurrence, a 10-year study.

• Authors : Casenaz, Alice; Piroth, Lionel; Labattut, Ludovic

Subjects: INFECTIOUS arthritis; GRAM-negative bacteria; RETROSPECTIVE studies

• Source: Journal of Infection; Nov2022, Vol. 85 Issue 5, p492-498, 7p

Record details

Clinical manifestations and antimicrobial susceptibility of Nocardia species at a tertiary hospital in Taiwan, 2011-2020.

• Authors : Lao, Chong Kei; Tseng, Mei-Chueh; Chiu, Cheng-Hsun

Subjects: ANTIBIOTICS; CEFTRIAXONE; SPECIALTY hospitalsTAIWAN

• Source: Journal of the Formosan Medical Association; Oct2022, Vol. 121 Issue 10, p2109-2122, 14p

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Rapid detection of imipenem/relebactam susceptibility/resistance in Enterobacterales.

• Authors : Bouvier, Maxime^1,2 (AUTHOR); Raro, Otávio Hallal Ferreira¹ (AUTHOR); Kerbol, Auriane² (AUTHOR)

Subjects: *MEDICAL microbiology; *IMIPENEM; *BACTERIAL growth

• Source: Clinical Microbiology & Infection. Nov2023, Vol. 29 Issue 11, p1453.e1-1453.e5. 1p.

Record details

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020.

• Authors : Karlowsky, James A.^1,2 (AUTHOR); Lob, Sibylle H.¹ (AUTHOR) ; Chen, Wei-Ting³ (AUTHOR)

Subjects: *PSEUDOMONAS aeruginosa; *IMIPENEM; *KLEBSIELLA pneumoniaePACIFIC Area

• Source: International Journal of Antimicrobial Agents. Sep2023, Vol. 62 Issue 3, pN.PAG-N.PAG. 1p.

Record details

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States — SMART 2015–2017.

• Authors : Karlowsky, James A.¹ (AUTHOR); Lob, Sibylle H.¹ (AUTHOR) ; Young, Katherine¹ (AUTHOR)

Subjects: *IMIPENEM; *PSEUDOMONAS aeruginosa; *PATHOLOGICAL laboratoriesUNITED States

• Source: Diagnostic Microbiology & Infectious Disease. Oct2019, Vol. 95 Issue 2, p212-215. 4p.

Record details

Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series.

• Authors : Jones, Lee Ann¹ (AUTHOR); Doucette, Lorna¹ (AUTHOR); Dellon, Elisabeth P.¹ (AUTHOR)

Subjects: *CYSTIC fibrosis; *IMIPENEM; *LUNG infections

• Source: Journal of Cystic Fibrosis. Jul2019, Vol. 18 Issue 4, pe42-e44. 3p.

Record details

Impact of CLSI and EUCAST breakpoint discrepancies on reporting of antimicrobial susceptibility and AMR surveillance.

• Authors : Cusack, T.P.^1,2 (AUTHOR) ; Ashley, E.A.^3,4 (AUTHOR); Ling, C.L.^4,5 (AUTHOR)

Subjects: *IMIPENEM; *MICROBIAL sensitivity tests; *LABORATORY management

• Source: Clinical Microbiology & Infection. Jul2019, Vol. 25 Issue 7, p910-911. 2p.

Record details